

### REMARKS

Support for new claims 65-74 can be found throughout the specification as originally filed, notably at page 10, lines 2-9, Example 11, and claims 7-8 as originally filed.


### CONCLUSION

The Applicants believe that the pending claims are in condition for allowance and early notification thereof is requested.

The Commissioner is hereby authorized to charge any additional fees which may be required in this application to Deposit Account No. 50-1214.

Respectfully submitted,

KATTEN MUCHIN ZAVIS

By:   
David W. Clough, Ph.D.  
Registration No.: 36,107

Dated: March 22, 2002  
KATTEN MUCHIN ZAVIS  
525 W. Monroe Street, Suite 1600  
Chicago, IL 60661  
Telephone: (312) 902-5464  
Fax: (312) 577-8736



RECEIVED

APR 05 2002

TECH CENTER 1600/2900

**APPENDIX TO AMENDMENT PURSUANT TO 37 C.F.R. § 1.121(c)(1)(ii)**

Pursuant to 37 C.F.R. § 1.121(c)(1)(ii), Applicant presents herewith marked-up text of the claims of this application as amended by the foregoing amendment.

65. (New) An antibody that specifically binds to a polypeptide comprising a sequence set forth in SEQ ID NO:4.
66. (New) An antibody that specifically binds to a polypeptide selected from the group consisting of a fragment, variant, analog, homolog and derivative of the sequence set forth in SEQ ID NO:4.
67. (New) An antibody that specifically binds to a polypeptide comprising a fusion protein, said fusion protein comprising a sequence set forth in SEQ ID NO:4.
68. (New) The antibody according to claim 65, wherein said antibody further comprises a label.
69. (New) The antibody according to claim 68, wherein said label is selected from the group consisting of an enzyme, protein, peptide, antigen, antibody, lectin, carbohydrate, biotin, avidin, radioisotope, toxin and heavy metal.
70. (New) An antibody according to any one of claims 65-69, wherein said antibody is a humanized antibody.
71. (New) An antibody according to any one of claims 65-69, wherein said antibody is a CDR-grafted antibody.

72. (New) An antibody according to any one of claims 65-69, wherein said antibody is a chimeric antibody.

73. (New) An antibody according to any one of claims 65-69, wherein said antibody is an antibody fragment.

74. (New) An antibody according to any one of claims 65-69, wherein said antibody is a monoclonal antibody.